Press releases
- Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
- Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023
- Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients
- Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
- Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
- Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau
- Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024
More ▼
Key statistics
On Friday, Everest Medicines Ltd (6HN:FRA) closed at 2.52, -31.15% below its 52-week high of 3.66, set on Nov 02, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.52 |
---|---|
High | 2.52 |
Low | 2.52 |
Bid | 2.48 |
Offer | 2.72 |
Previous close | 2.46 |
Average volume | 0.00 |
---|---|
Shares outstanding | 324.70m |
Free float | 194.05m |
P/E (TTM) | -- |
Market cap | 7.16bn HKD |
EPS (TTM) | -2.92 HKD |
Data delayed at least 15 minutes, as of May 31 2024 07:14 BST.
More ▼